Cancer UrologyCancer UrologyОнкоурология1726-97761996-1812Publishing House ABV Press17010.17650/1726-9776-2011-7-2-96-100REVIEWОБЗОРPROSTATE CRYOABLATIONКРИОАБЛЯЦИЯ ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫGovorovA. V.ГоворовА. В.
Russian Federation
alexgovorov@newmail.ruPushkarD. Yu.ПушкарьД. Ю.
Russian Federation
alexgovorov@newmail.ruIvanovV. Yu.ИвановВ. Ю.
Russian Federation
alexgovorov@newmail.ruDepartment of Urology, Moscow State University of Medicine and DentistryКафедра урологии МГМСУCity Clinical Hospital № 50, MoscowГКБ № 50, Москва3006201172961003007201430072014https://oncourology.abvpress.ru/oncur/article/view/170

Prostate cryoablation is an effective mini-invasive treatment for prostate cancer (PC), which may be used in case of both primary and postradiotherapy recurrent tumor. Due to continuous improvements of cryoablation equipment, the number of treatment-induced complications is small. The studies oflong-term cryotherapy outcomes, such as cancer-specific, metastasis-free, and other survival rates, are presently under way. Focal cryoablation of the prostate remains an experimental therapy option.

Криоабляция предстательной железы является эффективным, минимально инвазивным методом лечения рака предстательной железы (РПЖ), который может применяться как первично, так и в случае рецидива опухоли после лучевой терапии. Благодаря постоянному усовершенствованию оборудования для криоабляции число осложнений лечения невелико. Изучение отдаленных результатов криотерапии РПЖ – раковоспецифической выживаемости, выживаемости без метастазов и др. – продолжается в настоящее время. Фокальная криоабляция предстательной железы остается экспериментальным видом терапии.

cryoablationprostate cancerfocal therapyкриоабляциярак предстательной железыфокальная терапия1. Patel B.G., Parsons C.L., Bidair M. et al. Cryoablation for carcinoma of the prostate. J Surg Oncol 1996;63:256–64.Patel B.G., Parsons C.L., Bidair M. et al. Cryoablation for carcinoma of the prostate. J Surg Oncol 1996;63:256–64.2. Lam J.S., Shvarts O., Belldegrun A.S. A new era for cryotherapy of prostate cancer? Cont Urol 2004;16(10):46–61.Lam J.S., Shvarts O., Belldegrun A.S. A new era for cryotherapy of prostate cancer? Cont Urol 2004;16(10):46–61.3. Gonder M.J., Soanes W.A., Schulman S. Cryosurgical treatment of the prostate. Invest Urol 1966;3:372–8.Gonder M.J., Soanes W.A., Schulman S. Cryosurgical treatment of the prostate. Invest Urol 1966;3:372–8.4. Flocks R.H., Nelson C.M., Boatman D.L. Perineal cryosurgery for prostatic carcinoma. J Urol 1972;108:933–5.Flocks R.H., Nelson C.M., Boatman D.L. Perineal cryosurgery for prostatic carcinoma. J Urol 1972;108:933–5.5. Megalli M.R., Gursel E.O., Veenema R.J. Closed perineal cryosurgery in prostate cancer. New probe and technique. Urology 1974;4:220–2.Megalli M.R., Gursel E.O., Veenema R.J. Closed perineal cryosurgery in prostate cancer. New probe and technique. Urology 1974;4:220–2.6. Onik G. Transrectal ultrasound-guided percutaneous radical cryosurgical ablation of the prostate. Cancer 1993;72:1291–9.Onik G. Transrectal ultrasound-guided percutaneous radical cryosurgical ablation of the prostate. Cancer 1993;72:1291–9.7. Lee F. US-guided percutaneous cryoablation of the prostate cancer. Radiology 1994;192:769–6.Lee F. US-guided percutaneous cryoablation of the prostate cancer. Radiology 1994;192:769–6.8. Cohen J., Miller R.J., Shuman B.A. Urethral warming catheter for use during cryoablation of the prostate. Urology 1995;45:861–4.Cohen J., Miller R.J., Shuman B.A. Urethral warming catheter for use during cryoablation of the prostate. Urology 1995;45:861–4.9. Tatsutani K., Rubinsky M., Onik G. et al. Effect of thermal variables on frozen human primary prostatic adenocarcinoma cells. Urology 1996;48:441–7.Tatsutani K., Rubinsky M., Onik G. et al. Effect of thermal variables on frozen human primary prostatic adenocarcinoma cells. Urology 1996;48:441–7.10. Baust J.G., Gage A.A. The molecular basis of cryosurgery. BJU International 2005;95:1187–91.Baust J.G., Gage A.A. The molecular basis of cryosurgery. BJU International 2005;95:1187–91.11. Gage A.A., Baust J. Mechanisms of tissue injury in cryosurgery. Cryobiology 1998;37(3):171–86.Gage A.A., Baust J. Mechanisms of tissue injury in cryosurgery. Cryobiology 1998;37(3):171–86.12. Larsson T.R., Robertson D.W., Corica A. et al. In vivo interstitial temperature mapping of the human prostate during cryosurgery with correlation to histopathologic outcomes. Urology 2000;55(4):547–52.Larsson T.R., Robertson D.W., Corica A. et al. In vivo interstitial temperature mapping of the human prostate during cryosurgery with correlation to histopathologic outcomes. Urology 2000;55(4):547–52.13. Cytron S., Greene D., Witzsch U. et al. Cryoablation of the prostate: technical recommendations. Prostate Cancer Prostatic Dis 2009;1:1–8.Cytron S., Greene D., Witzsch U. et al. Cryoablation of the prostate: technical recommendations. Prostate Cancer Prostatic Dis 2009;1:1–8.14. Babaian R.J., Donnelly B., Bahn D. et al. Best practice statement on cryosurgery for the treatment of localized prostate cancer. J Urol 2008;180:1993–2004.Babaian R.J., Donnelly B., Bahn D. et al. Best practice statement on cryosurgery for the treatment of localized prostate cancer. J Urol 2008;180:1993–2004.15. Long J.P., Bahn D., Lee F. et al. Five-year retrospective, multi-institutional pooled analysis of cancer-related outcomes after cryosurgical ablation of the prostate. Urology 2001;57(3):518–23.Long J.P., Bahn D., Lee F. et al. Five-year retrospective, multi-institutional pooled analysis of cancer-related outcomes after cryosurgical ablation of the prostate. Urology 2001;57(3):518–23.16. Donnelly B.J., Saliken J.C., Ernst D.S. et al. Prospective trial of cryosurgical ablation of the prostate: five-year results. Urology 2002; 60(4):645–9.Donnelly B.J., Saliken J.C., Ernst D.S. et al. Prospective trial of cryosurgical ablation of the prostate: five-year results. Urology 2002; 60(4):645–9.17. Jones J.S., Rewcastle J.C., Donnelly B.J. et al. Whole gland primary prostate cryoablation: initial results from the Cryo On-line Data Registry. J Urol 2008;180:554–8.Jones J.S., Rewcastle J.C., Donnelly B.J. et al. Whole gland primary prostate cryoablation: initial results from the Cryo On-line Data Registry. J Urol 2008;180:554–8.18. Roach M. III, Hanks G., Thames H. Jr. et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006;65:965–74.Roach M. III, Hanks G., Thames H. Jr. et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006;65:965–74.19. Cohen J.K., Miller R.J., Ahmed S. et al. Ten-year biochemical disease ontrol for patients with prostate cancer treated with cryosurgery as primary therapy. Urology 2008;71:515–8.Cohen J.K., Miller R.J., Ahmed S. et al. Ten-year biochemical disease ontrol for patients with prostate cancer treated with cryosurgery as primary therapy. Urology 2008;71:515–8.20. Levy D.A., Pisters L.L., Jones J.S. Primary cryoablation nadir prostate specific antigen and biochemical failure. J Urol 2009;182:931–7.Levy D.A., Pisters L.L., Jones J.S. Primary cryoablation nadir prostate specific antigen and biochemical failure. J Urol 2009;182:931–7.21. Levy D., Avallone A., Jones J.S. Current state of urological cryosurgery: prostate and kidney. BJU Int 2010;105:590–600.Levy D., Avallone A., Jones J.S. Current state of urological cryosurgery: prostate and kidney. BJU Int 2010;105:590–600.22. Prepelica K.L., Okeke Z., Murphy A. et al. Cryosurgical ablation of the prostate: high risk patient outcomes. Cancer 2005;15:1625–30.Prepelica K.L., Okeke Z., Murphy A. et al. Cryosurgical ablation of the prostate: high risk patient outcomes. Cancer 2005;15:1625–30.23. Han K.R., Cohen J.K., Miller R.J. et al. Treatment of organ confined prostate cancer with third generation cryosurgery: preliminary multicenter experience. J Urol 2003;170(4 Pt 1): 1126–30.Han K.R., Cohen J.K., Miller R.J. et al. Treatment of organ confined prostate cancer with third generation cryosurgery: preliminary multicenter experience. J Urol 2003;170(4 Pt 1): 1126–30.24. Bahn D.K., Lee F., Badalament R. et al. Targeted cryoablation of the prostate: 7-year outcomes in the primary treatment of prostate cancer. Urology 2002;60(2 Suppl 1):3–11.Bahn D.K., Lee F., Badalament R. et al. Targeted cryoablation of the prostate: 7-year outcomes in the primary treatment of prostate cancer. Urology 2002;60(2 Suppl 1):3–11.25. Chin J.L., Lim D., Abdelhady M. Review of primary and salvage cryoablation for prostate cancer. Cancer Control 2007;14(3):231–7.Chin J.L., Lim D., Abdelhady M. Review of primary and salvage cryoablation for prostate cancer. Cancer Control 2007;14(3):231–7.26. Pisters L.L., Leibovici D., Blute M. et al. Locally recurrent prostate cancer after initial radiation therapy: a comparison of salvage radical prostatectomy versus cryotherapy. J Urol 2009;182:517–27.Pisters L.L., Leibovici D., Blute M. et al. Locally recurrent prostate cancer after initial radiation therapy: a comparison of salvage radical prostatectomy versus cryotherapy. J Urol 2009;182:517–27.27. Izawa J.I., Perrotte P., Greene G.F. et al. Local tumor control with salvage cryotherapy for locally recurrent prostate cancer after external beam radiotherapy. J Urol 2001;165:867–70.Izawa J.I., Perrotte P., Greene G.F. et al. Local tumor control with salvage cryotherapy for locally recurrent prostate cancer after external beam radiotherapy. J Urol 2001;165:867–70.28. Spiess P.E., Lee A.K., Leibovici D. et al. Presalvage prostate-specific antigen and PSAdoubling time as predictors of biochemical failure of salvage cryotherapy in patients with locally recurrent prostate cancer after radiotherapy. Cancer 2006;107:275–80.Spiess P.E., Lee A.K., Leibovici D. et al. Presalvage prostate-specific antigen and PSAdoubling time as predictors of biochemical failure of salvage cryotherapy in patients with locally recurrent prostate cancer after radiotherapy. Cancer 2006;107:275–80.29. Levy D.A., Pisters L.L., Jones J.S. Impact of nadir post salvage cryoablation prostate specific antigen level on biochemical disease-free survival. Chicago, Il: Annual Meeting AUA 2009:abstr. 1981.Levy D.A., Pisters L.L., Jones J.S. Impact of nadir post salvage cryoablation prostate specific antigen level on biochemical disease-free survival. Chicago, Il: Annual Meeting AUA 2009:abstr. 1981.30. Donnelly B.J., Saliken J.C., Ernst D.S. et al. Role of transrectal ultrasound guided salvage cryosurgery for recurrent prostate carcinoma after radiotherapy. Prostate Cancer Prostatic Dis 2005;8:235–42.Donnelly B.J., Saliken J.C., Ernst D.S. et al. Role of transrectal ultrasound guided salvage cryosurgery for recurrent prostate carcinoma after radiotherapy. Prostate Cancer Prostatic Dis 2005;8:235–42.31. Ghafar M.A., Johnson C.W., De la Taille A. et al. Salvage cryotherapy using an argon based system for locally recurrent prostate cancer after radiation therapy: the Columbia experience. J Urol 2001;166:1333–8.Ghafar M.A., Johnson C.W., De la Taille A. et al. Salvage cryotherapy using an argon based system for locally recurrent prostate cancer after radiation therapy: the Columbia experience. J Urol 2001;166:1333–8.32. Chin J.L., Pautler S.E., Mouraviev V. et al. Results of salvage cryoablation of the prostate after radiation: identifying predictors of treatment failure and complications. J Urol 2001;165(6 Pt 1): 1937–41.Chin J.L., Pautler S.E., Mouraviev V. et al. Results of salvage cryoablation of the prostate after radiation: identifying predictors of treatment failure and complications. J Urol 2001;165(6 Pt 1): 1937–41.33. Pisters L.L., von Eschenbach A.C., Scott S.M. et al. The efficacy and complications of salvage cryoyherapy of the prostate. J Urol 1997;157(3):921–5.Pisters L.L., von Eschenbach A.C., Scott S.M. et al. The efficacy and complications of salvage cryoyherapy of the prostate. J Urol 1997;157(3):921–5.34. Shelley M., Wilt T.J., Coles B. et al. Cryotherapy for localised prostate cancer. Cochrane Database Syst Rev 2007, July 18(3): CD005010.Shelley M., Wilt T.J., Coles B. et al. Cryotherapy for localised prostate cancer. Cochrane Database Syst Rev 2007, July 18(3): CD005010.35. Onik G., Narayan P., Vaughan D. et al. Focal “nerve-sparing” cryosurgery for treatment of primary prostate cancer: a new approach to preserving potency. Urology 2002;60(1):109–14.Onik G., Narayan P., Vaughan D. et al. Focal “nerve-sparing” cryosurgery for treatment of primary prostate cancer: a new approach to preserving potency. Urology 2002;60(1):109–14.36. Lambert E.H., Bolte K., Masson P. et al. Focal cryosurgery: encouraging health outcomes for unifocal prostate cancer. Urology 2007;69:1117–20.Lambert E.H., Bolte K., Masson P. et al. Focal cryosurgery: encouraging health outcomes for unifocal prostate cancer. Urology 2007;69:1117–20.37. Onik G., Vaughan D., Lotenfoe R. et al. The “male lumpectomy”: focal therapy for prostate cancer using cryoablation results in 48 patients with at least 2-year follow-up. Urol Oncol 2008;26:500–5.Onik G., Vaughan D., Lotenfoe R. et al. The “male lumpectomy”: focal therapy for prostate cancer using cryoablation results in 48 patients with at least 2-year follow-up. Urol Oncol 2008;26:500–5.38. Barqawi A., Crawford E.D. Focal therapy in prostate cancer: future trends. BJU International 2005;95:273–4.Barqawi A., Crawford E.D. Focal therapy in prostate cancer: future trends. BJU International 2005;95:273–4.